Physician

Ramadevi Medavarapu, M.D

According to 2025 Medicare claims, Ramadevi Medavarapu, M.D (NPI: 1427298520) practices hematology/oncology in the Las Cruces, NM market, with the plurality of this provider's patient population coming from Dona Ana, NM. This provider's primary affiliated billing organization is RIO GRANDE HEMATOLOGY AND ONCOLOGY, LLC (NPI: 1871134692; TIN: 37-1915692) and primary practice location at 88011-8255.

Medavarapu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 461 traditional Medicare patients, billed 216,343 HCPCS/CPT codes, and received $3,428,507 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,828 prescription claims across 405 beneficiaries totaling $7,711,580 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 30 claims. Open Payments data shows 24 records totaling $531. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $67,493 to $3,428,507. Similarly, Part D prescription costs have risen steadily, from $595,633 to $7,711,580. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	163	627	$67,493
2016	177	839	$88,385
2017	175	769	$75,373
2018	199	799	$81,583
2019	224	874	$90,044
2020	232	45,160	$872,420
2021	391	146,278	$2,832,168
2022	485	193,078	$3,297,261
2023	549	222,039	$3,144,441
2024	461	216,343	$3,428,507

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	78	410	$595,633
2016	100	594	$631,158
2017	112	671	$709,857
2018	120	818	$1,824,016
2019	141	855	$2,128,637
2020	155	965	$1,680,458
2021	194	1,373	$3,449,963
2022	273	1,748	$4,669,744
2023	341	2,125	$5,721,650
2024	405	2,828	$7,711,580

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	53	$3,263
2019	N/R	11	$224
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	25	$1,424
2023	N/R	30	$10,232
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	92	92	$142
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	228	784	$116
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	212	332	$79
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	178	234	$54
36415	Insertion of needle into vein for collection of blood sample	387	1,484	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	46	1,288	$928,394
Cabometyx	Cabozantinib S-Malate	36	1,080	$827,120
Scemblix	Asciminib Hydrochloride	25	750	$527,747
Promacta	Eltrombopag Olamine	14	420	$486,510
Venclexta	Venetoclax	40	1,174	$467,684

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	24	$531	PROGENICS PHARMACEUTICALS, INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ramadevi Medavarapu, M.D?

Tedicare shows public-source Medicare data for Ramadevi Medavarapu, M.D (NPI 1427298520), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ramadevi Medavarapu, M.D have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ramadevi Medavarapu, M.D?

Ramadevi Medavarapu, M.D is linked to RIO GRANDE HEMATOLOGY AND ONCOLOGY, LLC (billing NPI 1871134692) in the available physician profile data.

Does Ramadevi Medavarapu, M.D have Open Payments data?

Ramadevi Medavarapu, M.D has 24 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.